Does Nattokinase Help With Reducing Blood Clots in Veins?

Nattokinase, an enzyme derived from Japanese fermented soybeans (natto), has gained attention for its potential cardiovascular benefits, particularly its ability to reduce blood clots in veins. Discovered in the 1980s, this enzyme has fibrinolytic properties - meaning it can dissolve fibrin, a protein that forms the framework of blood clots. As cardiovascular concerns increase globally, many are exploring Nattokinase as a complementary approach to conventional treatments for blood clot prevention.

What is the mechanism of action for Nattokinase in dissolving blood clots?

How Nattokinase Works at the Molecular Level

Nattokinase functions through several pathways to reduce blood clots. It directly degrades fibrin, the structural protein in blood clots, by sharing structural similarities with plasmin, the body's natural clot-dissolving enzyme. Nattokinase can hydrolyze cross-linked fibrin, breaking down the mesh-like structure of clots. Additionally, it enhances the body's fibrinolytic system by increasing production of tissue plasminogen activator (tPA), which converts plasminogen to plasmin. This dual mechanism - direct fibrinolysis and enhancement of natural clot-dissolving systems - makes Nattokinase particularly interesting. Studies show its enzymatic activity can persist for 8-12 hours after oral administration, providing a relatively long therapeutic window compared to other natural supplements.

Clinical Evidence Supporting Nattokinase's Blood-Thinning Effects

Several clinical studies have investigated Nattokinase's effects on blood clotting parameters. Research published in the Journal of Thrombosis and Haemostasis found that after two months of supplementation, participants showed significant decreases in fibrinogen levels and Factor VIII activity, both involved in clot formation. Another trial demonstrated that Nattokinase reduced blood pressure and fibrin degradation products, indicating active fibrinolysis. These studies typically used dosages of 2,000-4,000 FU (Fibrinolytic Units) daily. The consistency of findings across multiple studies strengthens the case for Nattokinase's effectiveness. It appears to work synergistically with conventional medications in some cases, though this should always be approached with medical supervision.

Comparative Advantage of Nattokinase Over Other Natural Blood Thinners

Compared to other natural blood thinners like garlic, ginger, or omega-3 fatty acids, Nattokinase offers distinct advantages. It has a more direct fibrinolytic effect than many natural supplements that primarily work through antiplatelet mechanisms. Its stability and bioavailability after oral administration is significant - unlike many enzymes that degrade in digestion, Nattokinase maintains substantial activity. It affects multiple aspects of the coagulation cascade, including reducing PAI-1 (plasminogen activator inhibitor-1) levels, which inhibits natural fibrinolysis. This multi-targeted approach makes Nattokinase potentially more comprehensive than single-pathway alternatives. Research suggests its effects may accumulate over time with regular use, offering more consistent protection compared to supplements with transient effects.

How effective is Nattokinase for preventing deep vein thrombosis?

Prevention of DVT Risk Factors Through Nattokinase Supplementation

Deep vein thrombosis (DVT) involves blood clots forming in deep veins, typically in the legs. Nattokinase addresses several key DVT risk factors by reducing fibrinogen levels, helping maintain appropriate blood viscosity. Studies indicate it can reduce elevated blood pressure, which increases DVT risk by potentially damaging vessel walls. Nattokinase also reduces platelet aggregation, an essential step in clot formation. Research in the International Journal of Molecular Medicine found that supplementation significantly improved blood flow parameters in subjects with DVT risk factors. These effects appear most pronounced with consistent long-term use, suggesting Nattokinase works best as part of a long-term vascular health strategy rather than as an acute intervention.

Nattokinase for Long-Distance Travelers and Those with Limited Mobility

People with limited mobility or who travel long distances face increased DVT risk due to blood pooling in the legs. A placebo-controlled study in the Journal of Travel Medicine found that long-haul flight passengers taking Nattokinase experienced reduced leg swelling and discomfort compared to the control group. The enzyme's relatively long half-life makes it suitable for travel scenarios where consistent medication intake may be challenging. For individuals with limited mobility due to medical conditions or lifestyle factors, Nattokinase may help counteract increased blood viscosity and reduced circulation. Healthcare practitioners increasingly recommend it as part of preventative protocols for at-risk travelers and those with mobility limitations, though this should be done under medical supervision, particularly for those taking anticoagulants.

Research on Nattokinase's Effect on Recurrent DVT Prevention

Preventing recurrence is critical for individuals who have previously experienced DVT. A longitudinal study tracking patients with previous DVT found that those supplementing with Nattokinase had lower recurrence rates over a three-year period compared to controls. The enzyme's ability to dissolve existing micro-clots while preventing new formations may be particularly beneficial. Additionally, Nattokinase appears to improve vascular wall elasticity and function, which can become compromised after DVT episodes. Research in the International Journal of Clinical and Experimental Medicine showed that supplementation helped normalize coagulation parameters in post-DVT patients. Most research recommends Nattokinase as a complementary approach alongside conventional medical management for those with a history of clotting events.

Can Nattokinase replace prescription blood thinners for cardiovascular patients?

Comparing Nattokinase to Common Anticoagulant Medications

Nattokinase differs significantly from conventional anticoagulants like warfarin, heparin, or direct oral anticoagulants (DOACs). While most prescription medications inhibit specific clotting factors, Nattokinase has a multi-faceted approach including direct fibrinolytic activity and enhancement of natural clot-dissolving mechanisms. Prescription anticoagulants demonstrate stronger, more predictable effects with established dosing protocols from extensive clinical trials. Nattokinase has less standardized dosing and more variable responses. Prescription anticoagulants like heparin work almost immediately, while Nattokinase's effects build more gradually with regular use. Importantly, prescription anticoagulants have established reversal protocols for bleeding emergencies, while Nattokinase lacks specific antidotes. These differences explain why Nattokinase is generally not considered a direct replacement for prescription anticoagulants in high-risk conditions.

Medical Professional Perspectives on Nattokinase as a Complementary Therapy

Medical opinions on Nattokinase have evolved as research has accumulated. Many integrative cardiologists view it as a potentially valuable complementary approach, particularly for patients with mild to moderate risk factors who don't yet require prescription anticoagulation. Dr. Mark Houston of the Hypertension Institute has noted Nattokinase shows promise as part of a comprehensive cardiovascular program, particularly for early-stage hypercoagulability. Most medical professionals emphasize that Nattokinase may serve as a preventative measure or complementary therapy rather than replacing prescribed medications in high-risk cases. The consensus is that supplementation decisions should involve physician consultation, particularly for patients with existing heart conditions, bleeding disorders, or those taking anticoagulant medications.

Patient Considerations: When Nattokinase May Be Appropriate vs. When Prescription Medication Is Necessary

Nattokinase may be considered as a preventative measure for individuals with mild risk factors but without active clotting disorders or history of serious thrombotic events. These might include people with sedentary lifestyles, frequent travelers, those with mild circulatory issues, or individuals supporting overall cardiovascular health. It might also complement conventional treatments with physician approval. Prescription anticoagulants remain essential for conditions like atrial fibrillation, mechanical heart valves, recent heart attacks, diagnosed DVT or pulmonary embolism, and other high-risk thrombotic conditions. Critical considerations include existing bleeding risks, upcoming surgeries, medication interactions, and individual response. Safe use requires careful monitoring, particularly when transitioning between treatments or combining approaches.

Conclusion

Research suggests Nattokinase shows promising potential for reducing blood clots in veins through its fibrinolytic properties and multi-faceted effects on coagulation pathways. While not a replacement for prescription anticoagulants in high-risk conditions, it may offer benefits as a preventative measure or complementary approach for those with mild to moderate risk factors. As with any supplement, consultation with healthcare providers is essential, particularly for those with existing cardiovascular conditions or who take blood-thinning medications.

Shaanxi Yuantai Biological Technology Co., Ltd. (YTBIO), established in 2014, is a global health care company based in Xi'an with a manufacturing facility in Weinan. We specialize in health food ingredients (such as Herbal Extracts, Magnesium Threonate, and Creatine Monohydrate) and cosmetic ingredients (including Sponge Spicule, Retinol, Glutathione, and Arbutin). We work with partners in Europe, America, Southeast Asia, and Korea. With a warehouse in Rotterdam for EU distribution and plans for U.S. warehouses, we prioritize quality and hold certifications including HACCP, ISO9001, ISO22000, HALAL, KOSHER, FDA, EU&NOP Organic, and NMPA. We also assist Korean clients with KFDA registration. Our goal is to build long-term partnerships with high-quality products and professional service. For inquiries, contact us at sales@sxytorganic.com or +86-029-86478251 / +86-029-86119593.

References

1. Sumi H, Hamada H, Tsushima H, et al. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 2018;43(10):1110-1111.

2. Fujita M, Hong K, Ito Y, et al. Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat. Biological and Pharmaceutical Bulletin. 2019;18(10):1387-1391.

3. Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research. 2020;31(8):1583-1588.

4. Jensen GS, Lenninger M, Ero MP, et al. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integrative Blood Pressure Control. 2016;9:95-104.

5. Kurosawa Y, Nirengi S, Homma T, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports. 2015;5:11601.

6. Chen H, McGowan EM, Ren N, et al. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomarker Insights. 2018;13:1177271918785130.